Physician profile
John Meiser
NPI 1205820479
$28,851.16
in general payments reported to CMS, 2019-2025
43 companies · $7,439 in 2025
The $7,439 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,088 · 2020: $1,510 · 2021: $1,752 · 2022: $3,794 · 2023: $5,867 · 2024: $6,399 · 2025: $7,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $7,495 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,100.00 |
| Food and Beverage | $7,494.59 |
| Education | $111.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,114.96 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,714.88 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,602.48 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,054.69 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $862.46 | 2019-2025 | |
| Optinose US, INC. | $681.42 | 2019-2025 | |
| Grifols USA, LLC | $622.81 | 2019-2025 | Xembify |
| Covis Pharma Gmbh | $617.33 | 2019-2023 | |
| Csl Behring | $526.66 | 2019-2024 | Hizentra, Privigen |
| Kaleo, INC. | $455.11 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $442.02 | 2020-2025 | Cuvitru, Takhzyro |
| Abbvie INC. | $414.80 | 2022-2025 | |
| Pfizer INC. | $392.21 | 2019-2025 | |
| Genentech USA, INC. | $388.55 | 2019-2025 | Xolair, Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.24 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $289.93 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $252.92 | 2019-2025 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Octapharma USA, INC. | $216.73 | 2019-2022 | |
| Galderma Laboratories, L.P. | $178.65 | 2024-2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $176.04 | 2022-2023 | |
| Blueprint Medicines Corporation | $174.61 | 2023-2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $166.50 | 2020-2023 | |
| Leo Pharma INC. | $161.81 | 2022-2025 | Adbry, Anzupgo |
| Organon LLC | $142.34 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $123.41 | 2025 | Neffy |
| Shire North American Group INC | $114.08 | 2019 | |
| Hikma Pharmaceuticals USA | $101.89 | 2023-2024 | Ryaltris |
| Incyte Corporation | $79.67 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Pharming Healthcare, INC. | $53.00 | 2023-2025 | Ruconest |
| Greer Laboratories, INC. | $51.09 | 2024 | Palforzia |
| Aytu Biopharma, INC. | $47.10 | 2020-2024 | Karbinal |
| Regeneron Pharmaceuticals, INC. | $44.06 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $42.63 | 2021-2023 | |
| Lilly USA, LLC | $39.39 | 2024-2025 | Ebglyss |
| Circassia INC. | $32.95 | 2019 | |
| Gc Biopharma USA, INC. | $23.47 | 2024 | Alyglo |
| Uswm, LLC | $20.17 | 2021 | |
| Biocryst US Sales Co., LLC | $19.74 | 2024 | Orladeyo |
| Neos Therapeutics, LP | $17.86 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.97 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.77 | 2025 | Zoryve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.